We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Takara Bio USA Holdings, Inc. Announces the Acquisition of Curio Bioscience, Adding Spatial Biology to Its Broad Portfolio of Single-Cell Omics Solutions

Cells.
Credit: iStock.
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Takara Bio USA Holdings, Inc. (”TBUSH”) announced the acquisition of Curio Bioscience. This strategic acquisition combines two innovative spatial biology platforms with Takara Bio’s portfolio of single-cell genomics tools.


TBUSH is a wholly owned subsidiary of Takara Bio Inc. ("Takara Bio"), headquartered in Shiga, Japan. Takara Bio USA, Inc. ("TBUSA") is a wholly owned subsidiary of TBUSH. TBUSA and TBUSH are part of the global Takara Bio Group, which offers diverse life science products and services supporting discovery, translational, and clinical scientists in advancing their research.


The Curio Bioscience acquisition will extend the power of Takara Bio’s NGS solutions and give customers deeper insights into tissue spatial organization and molecular composition. “We are proud of our history of innovation in the single-cell genomics market, having developed the first commercially available kits for single-cell RNA- and DNA-seq,” said Carol Lou, President and CEO of Takara Bio USA. “The acquisition of Curio Bioscience continues this legacy with the addition of Trekker, the first truly single-cell spatial technology.” 

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE
Curio’s advanced Trekker and Seeker technologies integrate spatial information with molecular data, enabling researchers to transform single-cell sequencing data into spatially resolved maps. This transformation offers high-resolution insights into the organization and function of cells within their native tissue environments.


“Curio Bioscience is dedicated to creating innovative approaches that map the entire transcriptome with unparalleled sensitivity and resolution,” said Stephen Fodor, co-founder and CEO. “Combining Curio’s technology with Takara Bio’s vast NGS and single-cell tool set will provide customers with industry-leading solutions for their spatial biology needs.”


Through these advancements, Takara Bio has solidified its position as a leader in the single-cell genomics market by continually driving innovation and supporting groundbreaking research in the life science market for a wide range of applications in cancer biology, neuroscience, developmental biology, and immunology.